Proteomics Program Officer
The Clinical Proteomics Centers for Infectious Diseases and Biodefense apply state-of-the-art proteomics technologies for the discovery, qualification, and verification of protein biomarkers in well-defined clinical samples collected for infectious diseases caused by NIAID Category A-C biodefense pathogens and emerging and re-emerging infectious diseases. At the conclusion of the verification phase of each project conducted by the Clinical Proteomics Centers (CPCs), scientists from the CPCs and their collaborators will be allowed three months to prepare and submit a manuscript for publication prior to putting the associated data in the public domain via the CPC websites and other public databases as appropriate. Candidate biomarkers will then be made available to the scientific community on the centers' websites, where they will be freely available to the public.
Proteomic analyses on well-defined case versus control clinical samples will be performed by
The Clinical Proteomics Centers for Infectious Diseases and Biodefense are no longer accepting requests for collaborative research projects to identify candidate pathogen and/or host protein biomarkers.
Last Updated May 10, 2013